


# Listing of claims

## Claims:

1. (Currently amended) A method for treating a skin microcirculatory disorder (SMD) comprising topically administering ~~The use of a hydroxypyridonone of formulae (I-III):~~



wherein

R<sup>1</sup> represents a (C<sub>1</sub>-C<sub>10</sub>)- alkyl, (C<sub>1</sub>-C<sub>10</sub>)-alkenyl, (C<sub>1</sub>-C<sub>10</sub>)-alkoxy, (C<sub>1</sub>-C<sub>10</sub>) hydroxyalkyl, (C<sub>5</sub>-C<sub>12</sub>) -aralkyl, (C<sub>3</sub>-C<sub>12</sub>)-cycloalkyl, (C<sub>1</sub>-C<sub>8</sub>)- carboalkoxy or (C<sub>1</sub>-C<sub>8</sub>)- carbamyl, or a (C<sub>10</sub>-C<sub>30</sub>)-peptide or peptidomimetic moiety, or a (C<sub>3</sub>-C<sub>6</sub>) polyol or monosaccharide;

R<sup>2</sup> represents an hydrogen atom or a linear or branched, saturated or unsaturated lo (C<sub>1</sub>-C<sub>22</sub>)-acyl, optionally substituted by (C<sub>1</sub>-C<sub>8</sub>)-alkoxy, carboxy, (C<sub>1</sub>-C<sub>8</sub>) alkoxy carbonyl, amino, hydroxy, said amino and hydroxy being optionally (C<sub>1</sub>-C<sub>22</sub>)-acylated or - alkylated;

R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup>, each individually, represent a hydrogen atom, or (C<sub>1</sub>-C<sub>10</sub>)-alkyl, (C<sub>1</sub>-C<sub>10</sub>)- alkenyl, (C<sub>1</sub>-C<sub>10</sub>)-alkoxy, (C<sub>5</sub>-C<sub>12</sub> aryl) alkyl, (C<sub>5</sub>-C<sub>12</sub> )-cycloalkyl, (C<sub>1</sub>-C<sub>8</sub> carbo)-alkoxy or (C<sub>1</sub>-C<sub>8</sub>)-carbamyl group;

with the proviso that both R<sup>1</sup> and R<sup>3</sup> are not hydrogen;

~~and/or a dermatologically/cosmetically saltssalt thereof. for the manufacture of a topical medicament useful in the treatment of a skin microcirculatory disorder (SMD).~~

2. (Currently amended) A method Use according to claim 1, wherein the MSD skin microcirculatory disorder (SMD) is rosacea.

3. (Currently amended) A method Use according to claim 1, wherein the MSD skin microcirculatory disorder (SMD) is cutaneous vasculitis.

4. (Currently amended) A method Use according to claim 1, wherein the MSD skin microcirculatory disorder (SMD) is actinic purpura.

5. (Currently amended) A method Use according to claim 1, wherein the MSD skin microcirculatory disorder (SMD) is a skin capillaritis.

6. (Currently amended) A method Use- according to claim 8, wherein the skin capillaritis is selected in the group consisting of progressive pigmentary dermatosis, purpura annularis telangiectodes, lichen aureus, contact allergy skin capillaritis, ~~and lichens aureus~~, itching purpura, eczematid-like purpura, ~~and or~~ pigmented purpuric lichenoid dermatosis.


7. (Currently amended) A method Use- according to claim 1, wherein the ~~MSD~~ skin microcirculatory disorder (SMD) is a consequence of a traumatic intradermal haemorrhage selected in the group consisting of that is a drug-induced pigmented purpuric dermatosis ~~and or~~ a complication of sclerotherapy, lipoplasty ~~and or~~ tattooing.

8. (Currently amended) A method Use- according to claim 1, wherein R<sup>1</sup> and R<sup>2</sup> are methyl, R<sup>3</sup> and R<sup>4</sup> are hydrogens.

9. (Currently amended) A method Use- according to claim 1, wherein R<sup>1</sup> and R<sup>2</sup> are ethyl R<sup>3</sup> and R<sup>4</sup> are hydrogens.

10. (Currently amended) A method Use- according to claim 1, wherein ~~Rat~~R<sup>1</sup> is CH<sub>2</sub>CH<sub>2</sub>OH, R<sup>2</sup> is methyl or ethyl, and R<sup>3</sup> and R<sup>4</sup> are hydrogens.

11. (Currently amended) A method for the treatment of skin microcirculatory disorder (SMD) comprising ~~the local application~~ locally applying to a mammal in need thereof of a therapeutically effective amount of hydroxypyridonone compound according to ~~claim 1~~ of formulae (I-III):



wherein

R<sup>1</sup> represents a (C<sub>1</sub>-C<sub>10</sub>)- alkyl, (C<sub>1</sub>-C<sub>10</sub>)-alkenyl, (C<sub>1</sub>-C<sub>10</sub>)-alkoxy, (C<sub>1</sub>-C<sub>10</sub>) hydroxyalkyl, (C<sub>5</sub>-C<sub>12</sub>) -aralkyl, (C<sub>3</sub>-C<sub>12</sub>)-cycloalkyl, (C<sub>1</sub>-C<sub>8</sub>)- carboalkoxy or (C<sub>1</sub>-C<sub>8</sub>)- carbamyl, or a (C<sub>10</sub>-C<sub>30</sub>)-peptide or peptidomimetic moiety, or a (C<sub>3</sub>-C<sub>6</sub>) polyol or monosaccharide;

R<sup>2</sup> represents an hydrogen atom or a linear or branched, saturated or unsaturated (C<sub>1</sub>-C<sub>22</sub>)-acyl, optionally substituted by (C<sub>1</sub>-C<sub>8</sub>)-alkoxy, carboxy, (C<sub>1</sub>-C<sub>8</sub>) alkoxy carbonyl, amino, hydroxy, said amino and hydroxy being optionally (C<sub>1</sub>-C<sub>22</sub>)-acylated or - alkylated;

R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup>, each individually, represent a hydrogen atom, or (C<sub>1</sub>-C<sub>10</sub>)-alkyl, (C<sub>1</sub>-C<sub>10</sub>)- alkenyl, (C<sub>1</sub>-C<sub>10</sub>)-alkoxy, (C<sub>5</sub>-C<sub>12</sub> aryl) alkyl, (C<sub>5</sub>-C<sub>12</sub> )-cycloalkyl, (C<sub>1</sub>-C<sub>8</sub> carbo)-alkoxy or (C<sub>1</sub>-C<sub>8</sub>)-carbamyl group;

with the proviso that both  $R^1$  and  $R^3$  are not hydrogen;

~~and/or~~ a dermatologically/cosmetically acceptable salt thereof

in admixture with a dermatologically/cosmetically acceptable ~~ingredients and carriers~~ carrier.

12. (Currently amended) A method ~~Method~~ according to claim 11, for the treatment of rosacea, cutaneous vasculitis, ~~and or~~ actinic purpura.

13. (Currently amended) A method ~~Method~~ according to claim 14, for the treatment of progressive pigmented purpura, itching purpura, pigmented purpuric lichenoid dermatosis, purpura annularis telangiectodes, contact allergy skin capillaritis, ~~and or~~ lichens aureus.

14. (Currently amended) A method ~~Method~~ according to claim 14, for the treatment of traumatic skin haemorrhage, a complication of sclerotherapy, lipoplasty or tattooing, drug-induced pigmented purpuric dermatosis, ~~and or~~ actinic purpura.

15. (New) A method according to claim 11, wherein  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$ , each individually, represent a hydrogen atom.

16. (New) A method according to claim 11, wherein  $R^1$  and  $R^3$  each individually, represent ( $C_1$ - $C_4$ )- alkyl, hydroxyalkyl or alkoxy.

17. (New) A method according to claim 11, wherein said  $R^2$  acyl group is formed by unbranched, naturally occurring caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic, linoleic acid, alpha-linolenic acid, eleostearic, delta-linolenic acid, gondoic acid, dihomo- $\gamma$ -linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatekaenoic acid, docosapentaenoic acid, docosapentaenoic, docosahexaenoic acid, nervonic or a mixture thereof.

18. (New) A method according to claim 11, wherein said  $R^2$  acyl is a  $C_{1-8}$  which is branched at the carbon atom adjacent to the carbonyl group.

19. (New) A method according to claim 11, wherein said hydroxypyridonone is 1, 2 dimethyl-3-hydroxy-4-pyridinone (deferiprone); 1,2-diethyl-3-hydroxy-4-pyridinone; 1-methyl-2-ethyl-3-hydroxy-4-pyridinone; 1-methyl-2-ethyl-3-hydroxy-4 pyridinone or 1-methyl-2-(2-methoxy-ethyl)-3-hydroxy-4-pyridinone.